Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Grifols S.A. ADR (GRFS)

Grifols S.A. ADR (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,564,868
  • Shares Outstanding, K 678,540
  • Annual Sales, $ 6,100 M
  • Annual Income, $ 706,570 K
  • 60-Month Beta 0.59
  • Price/Sales 1.70
  • Price/Cash Flow 8.71
  • Price/Book 1.18
Trade GRFS with:

Options Overview

Details
  • Implied Volatility 35.58%
  • Historical Volatility 18.84%
  • IV Percentile 2%
  • IV Rank 9.62%
  • IV High 93.46% on 01/27/21
  • IV Low 29.42% on 06/09/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 46
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 1,537
  • Open Int (30-Day) 1,229

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.27
  • Number of Estimates 1
  • High Estimate 0.27
  • Low Estimate 0.27
  • Prior Year 0.35
  • Growth Rate Est. (year over year) -22.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.92 +3.95%
on 07/27/21
17.45 -11.12%
on 07/02/21
-1.84 (-10.61%)
since 06/30/21
3-Month
14.92 +3.95%
on 07/27/21
19.07 -18.67%
on 06/11/21
-2.14 (-12.12%)
since 04/30/21
52-Week
14.81 +4.73%
on 03/10/21
20.49 -24.30%
on 01/19/21
-3.80 (-19.68%)
since 07/30/20

Most Recent Stories

More News
Moving Average Crossover Alert: Grifols (GRFS)

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

GRFS : 15.45 (-0.77%)
Myasthenia Gravis Treatment Market Size, Share, Trends, Analysis and Forecast 2027

The report on Myasthenia Gravis Treatment provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

ARGX : 305.28 (+3.19%)
ALPMF : 17.7500 (+1.43%)
AVDL : 7.62 (-1.04%)
BAX : 77.45 (+0.09%)
GSK : 40.04 (-0.15%)
GRFS : 15.45 (-0.77%)
MTZPY : 18.6000 (-0.13%)
NVS : 92.36 (+0.18%)
RARX : 47.99 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

, /PRNewswire/ -- a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, today began commercializing HyperHEP B, a new...

GIKLY : 12.2400 (+1.16%)
GRF : 8.83 (-0.79%)
GRFS : 15.45 (-0.77%)
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona

- - , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health...

GIKLY : 12.2400 (+1.16%)
GRF : 8.83 (-0.79%)
GRFS : 15.45 (-0.77%)
Grifols: Q1 Earnings Snapshot

BARCELONA, Spain (AP) _ Grifols SA (GRFS) on Tuesday reported earnings of $156.7 million in its first quarter.

GRFS : 15.45 (-0.77%)
GIKLY : 12.2400 (+1.16%)
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and...

GIKLY : 12.2400 (+1.16%)
GRF : 8.83 (-0.79%)
GRFS : 15.45 (-0.77%)
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

, /PRNewswire/ --Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's...

GIKLY : 12.2400 (+1.16%)
GRF : 8.83 (-0.79%)
GRFS : 15.45 (-0.77%)
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

, /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange...

GRF : 8.83 (-0.79%)
GRFS : 15.45 (-0.77%)
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's...

GIKLY : 12.2400 (+1.16%)
GRF : 8.83 (-0.79%)
GRFS : 15.45 (-0.77%)
Grifols installs first-ever DG Reader Net analyzer in North America

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of innovative diagnostic solutions, today...

GIKLY : 12.2400 (+1.16%)
GRF : 8.83 (-0.79%)
GRFS : 15.45 (-0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

3rd Resistance Point 17.21
2nd Resistance Point 16.82
1st Resistance Point 16.19
Last Price 15.45
1st Support Level 15.18
2nd Support Level 14.79
3rd Support Level 14.16

See More

52-Week High 20.49
Fibonacci 61.8% 18.32
Fibonacci 50% 17.65
Fibonacci 38.2% 16.98
Last Price 15.45
52-Week Low 14.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar